Inventor
ZEMEDE GENET
US14 patents
⚠️ This page may combine multiple inventors who share the name “ZEMEDE GENET”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
PROTAGONIST THERAPEUTICS INC
8 patentsUS9518091B2Dec 13, 2016
A4B7 peptide monomer and dimer antagonists
PROTAGONIST THERAPEUTICS INC34 citations98
US10626146B2Apr 21, 2020
α4β7 thioether peptide dimer antagonists
PROTAGONIST THERAPEUTICS INC15 citations94
US10059744B2Aug 28, 2018
α4β7 thioether peptide dimer antagonists
PROTAGONIST THERAPEUTICS INC22 citations94
US9809623B2Nov 7, 2017
α4β7 peptide monomer and dimer antagonists
PROTAGONIST THERAPEUTICS INC26 citations94
US9714270B2Jul 25, 2017
a4B7 integrin thioether peptide antagonists
PROTAGONIST THERAPEUTICS INC27 citations94
US11111272B2Sep 7, 2021
α4α7 peptide monomer and dimer antagonists
PROTAGONIST THERAPEUTICS INC10 citations86
US10301371B2May 28, 2019
Cyclic monomer and dimer peptides having integrin antagonist activity
PROTAGONIST THERAPEUTICS INC19 citations85
US11840581B2Dec 12, 2023
α4β7 thioether peptide dimer antagonists
PROTAGONIST THERAPEUTICS INC1 citations73
AFFYMAX INC
4 patentsUS7084245B2Aug 1, 2006
Peptides that bind to the erythropoietin receptor
AFFYMAX INC181 citations97
US7528104B2May 5, 2009
Peptides that bind to the erythropoietin receptor
AFFYMAX INC15 citations83
US7414105B2Aug 19, 2008
Peptides that bind to the erythropoietin receptor
AFFYMAX INC6 citations72
US7855175B2Dec 21, 2010
Peptides that bind to the erythropoietin receptor
AFFYMAX INC3 citations62